- Home
- CMII vs ABEO Comparison
CMII vs ABEO Comparison
Compare CMII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMII | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.1M | 307.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CMII | ABEO |
|---|---|---|
| Price | $9.98 | $5.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 19.7K | ★ 851.8K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.76 | $4.00 |
| 52 Week High | $10.01 | $7.54 |
Technical Indicators
Market Signals| Indicator | CMII | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 69.25 | 55.78 |
| Support Level | N/A | $5.24 |
| Resistance Level | N/A | $6.01 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 70.00 | 68.79 |
Price Performance
Historical ComparisonAbout CMII Columbus Circle Capital Corp II Class A Ordinary Shares
Columbus Circle Capital Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.